April 23, 2021 Acad, Gov/Utilities Bio/Pharma/CRO Clinical Research/Diagn. PAI Top-10 PR/Corporate

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy

About 90,000 women globally die from endometrial cancer each year1 VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly) Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a... Read more

April 12, 2021 Bio/Pharma/CRO Liq. Handling & Robotics Product Launch

Expansion of Lonza’s Automated Robotic Solution for Endotoxin Testing Automates Sustainable Recombinant Factor C Assay

12 Apr 2021 Downloads News Release PDF The PyroTec® PRO Automated Solution combined with the PyroWave® Reader option expands the range of endotoxin testing types available on the platform to now include the PyroGene® Recombinant Factor C assay The addition of the PyroWave® XM Fluorescent Reader complements the existing absorbance readers used in traditional LAL-based assays Full integration with... Read more

April 12, 2021 Bio/Pharma/CRO

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%

Among individuals who still experienced symptomatic infections, those who received casirivimab and imdevimab were able to clear the virus faster and had much shorter symptom duration In a cohort of recently-infected asymptomatic patients, casirivimab and imdevimab reduced the overall risk of progressing to symptomatic COVID-19 by 31% Detailed results will be shared with regulatory authorities... Read more

March 23, 2021 Bio/Pharma/CRO Clinical Research/Diagn. PAI Top-10 Product Launch

New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19

Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by four days The 2,400 mg and 1,200 mg doses tested in the phase III study had similar efficacy across all endpoints Companion dose-ranging phase II trial showed significant and comparable viral reductions for a range of doses of casirivimab and... Read more

March 22, 2021 Bio/Pharma/CRO Informatics & Software Lab Top-10 M&A, Partnerships Mass Spectrometry

Thermo Fisher Scientific Collaborates with Protein Metrics to Optimize Mass Spectrometry Data Analysis for Biopharmaceutical and Proteomics Applications

Thermo Fisher Scientific Collaborates with Protein Metrics to Optimize Mass Spectrometry Data Analysis for Biopharmaceutical and Proteomics Applications Protein Metrics’ software solutions complement Thermo Fisher’s mass spectrometry systems to facilitate precise, reliable data processing and drive innovation GERMERING, Germany, March 22, 2021 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, and Protein Metrics,... Read more

March 22, 2021 Bio/Pharma/CRO

Pivotal Phase III study shows Roche’s Tecentriq helped people with early lung cancer live longer without their disease returning

First Phase III study to show that a cancer immunotherapy improves disease-free survival in people with resectable early stage lung cancer compared to best supportive care Treating lung cancer early, before it has spread, may help prevent the disease from returning and therefore provide the best opportunity for a cure Data will be submitted to... Read more

March 17, 2021 Bio/Pharma/CRO Lab Top-10

PerkinElmer Further Expands Industry-Leading Signals™ Informatics Capabilities in Biologics Drug Discovery

WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced its industry-leading documentation, workflow and decision making Signals™ informatics platform is being expanded to build on existing capabilities in the biologics drug discovery space. This comes through a collaboration with Insightful Science, a software company serving the global life sciences community. With... Read more

March 11, 2021 Bio/Pharma/CRO Microscopy

Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia

The REMDACTA clinical trial of Actemra/RoActemra plus Veklury did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone Roche will submit the REMDACTA results to a peer-reviewed journal Basel, 11 March 2021 – Roche (SIX: RO, ROG; OTCQX:... Read more

February 26, 2021 Bio/Pharma/CRO Lab Top-10 PAI Top-10

Thermo Fisher Scientific Completes Acquisition of Mesa Biotech

WALTHAM, Mass., Feb. 26, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has completed its previously announced acquisition of Mesa Biotech, Inc., a privately held point-of-care molecular diagnostic company. “Mesa Biotech is an important part of our strategy to expand the benefits of molecular diagnostics at... Read more

February 12, 2021 Bio/Pharma/CRO Product Launch

New phase III data show Roche’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients

Across four studies in diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), approximately half of people receiving faricimab could be treated every four months in the first year Approximately three-quarters of people receiving faricimab could be treated every three months or longer in the first year Faricimab showed rapid and consistent improvements in... Read more